June 08, 2021

Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc.

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. February 15, 2022

    Fed. Circ. Says 'Ad Hoc' Group Can't Revive Amarin Drug IP

    A Federal Circuit panel on Tuesday quickly shut down an effort by a self-described "ad hoc" group of Amarin Pharma Inc. shareholders to challenge a Nevada federal judge's decision to throw out six patents on Amarin's blockbuster heart drug Vascepa.

2 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS